mynth
← DATABASE
12/2021

KAVO DENTAL acquired by PLANMECA GROUP

GERMANY Life Sciences / Medical Devices EV 300M - 700M EUR

Context

Planmeca has successfully finalized the acquisition of the treatment unit and instrument business from a major diversified global medical manufacturer. This strategic transaction represents a significant consolidation of the global dental equipment market, bringing together two of the most technically advanced portfolios in the industry. The strategic rationale for the move centers on the high degree of industrial synergy between the target’s mechanical instrumentation excellence and the group's existing strength in digital 3D imaging and software interfaces. By integrating the target’s renowned heritage and manufacturing capabilities, the group establishes itself as a dominant single-source provider for complete dental operatory solutions. The acquisition includes the full transfer of iconic branding and intellectual property, allowing the organization to capitalize on a massive global installed base. The partnership is designed to accelerate the development of "connected" dental suites, where high-precision handpieces are synchronized with digital diagnostic platforms. This integration reinforces the group’s standing as a primary technical enabler for dental professionals, ensuring long-term technical durability and operational caliber across its international operational hubs.

KAVO DENTAL, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

KaVo Dental is a globally recognized industrial leader specializing in the development and manufacturing of high-performance dental instruments and comprehensive treatment centers. The organization's business model is built on a legacy of technical precision, producing a wide array of specialized handpieces, turbines, and integrated operatory units. Its value proposition is centered on ergonomic excellence, mechanical durability, and the integration of optical and fluid dynamic technologies into clinical workflows. Strategically, the firm focuses on the premium segment of the dental market, where it provides the foundational hardware required for high-stakes restorative and preventative procedures. By maintaining a focus on technical reliability and engineering innovation, the entity facilitates the operational efficiency of dental practices worldwide. The organization operates as a critical technical partner for practitioners seeking industrialized quality in medical instrumentation.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
LOGIN
LOGIN
LOGIN
2019
LOGIN
LOGIN
LOGIN

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
DateAcquirerTargetCountrySectorDeal Context
01/2022ARDIANBIOFARMA GROUPITALYLife Sciences

Ardian acquired a majority stake in Biofarma Group from White Bridge Investments. Ardian's entry is designed to transform the European leader into a global champion, specifically targeting expansion into the US and APAC markets while maintaining its technological lead in the high-margin probiotic segment

01/2022PERMIRABIO PRODUCTS LABORATORY (BPL)UNITED KINGDOMLife Sciences

Permira acquired BPL from its sole shareholder, Tiancheng International Investment (TII), which had owned the business since 2016. The acquisition was part of a larger strategic plan to merge BPL's robust US collection network and specialized rare disease portfolio with Kedrion

12/2021INTEGEROSCORUNITED STATESLife Sciences

Integer Holdings has successfully finalized the acquisition of Oscor, Inc., a strategic move designed to significantly broaden the group’s cardiovascular and neurostimulation product portfolios. This transaction integrates a robust range of proprietary products, including steerable sheaths and cardiac leads, into the acquirer’s existing medical device outsource framework

12/2021THE CARLYLE GROUP / GTCRRESONETICSUNITED STATESLife Sciences

The strategic investment in Resonetics by Carlyle signifies a major territorial and technical advancement for the organization, building upon the momentum of eight successful add-on acquisitions. The strategic rationale for this transaction centers on a "platform-acceleration" maneuver, merging the target's industry-leading technical operational depth in micro-manufacturing with the new sponsor’s extensive global network and expertise in healthcare digitalization

12/2021WINNCAREPHARMAOUEST INDUSTRIESFRANCELife Sciences

This transaction marks the first major structural acquisition for Winncare following the entry of Siparex ETI as its majority shareholder earlier in 2021. By acquiring 100% of Pharmaouest Industries, Winncare has significantly strengthened its industrial capabilities and product portfolio in the high-stakes segment of pressure ulcer prevention

11/2021COLOPLASTATOS MEDICALSWEDENLife Sciences

Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market

09/2021PERRIGO COMPANYHRA PHARMAFRANCELife Sciences

The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform

07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCELife Sciences

Intech Medical, a global leader in the manufacturing of orthopedic surgical instruments and implants, has entered into an agreement to be acquired by Montagu Private Equity. The transaction marks the exit of Eurazeo (specifically its mid-cap subsidiary) and Andera Partners, who have held a majority stake in the French group since 2017

07/2021PARTNERS GROUPPHARMATHENGREECELife Sciences

Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery

07/2021ORKLANUTRAQNorwayLife Sciences

Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of KAVO DENTAL by PLANMECA GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: kavo dental

Acquirer: planmeca group